Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 2/3 6Phase 4 5Phase 3 4Phase 1/2 3Phase 1 2Phase NA 1

Status

Unknown 4Completed 3Recruiting 2Withdrawn 1Terminated 1Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Breast Neoplasms 143Colorectal Neoplasms 97Carcinoma, Non-Small-Cell Lung 97Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 45Colonic Neoplasms 41Nasopharyngeal Carcinoma 39Leukemia, Myeloid, Acute 39Prostatic Neoplasms 38Lymphoma, Large B-Cell, Diffuse 38Uterine Cervical Neoplasms 36Neoplasm Metastasis 33Ovarian Neoplasms 32Esophageal Neoplasms 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 22Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Squamous Cell Carcinoma of Head and Neck 17Lymphoma, Mantle-Cell 17

Interventions

Vinorelbine 1Pemetrexed 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Unknown × NSCLC × Clear all
NCT03428022 2019-04-04

AFLC

Shenzhen People's Hospital

Phase 3 Unknown
54 enrolled
Thoracic

NSCLC

NCT03656393 2018-09-04

RCTACSCNSCLC

Shenzhen People's Hospital

Phase 3 Unknown
48 enrolled
Thoracic

NSCLC

NCT03269162 2017-09-14

Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection

Shanghai University of Traditional Chinese Medicine

Phase 3 Unknown
144 enrolled
Thoracic

NSCLC

NCT02140333 2015-02-12

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 3 Unknown
220 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡